Interactions between cisplatin derivatives and mobile phase during chromatographic separation

被引:20
作者
Heudi, O [1 ]
Cailleux, A [1 ]
Allain, P [1 ]
机构
[1] CHU ANGERS,LAB PHARMACOL & TOXICOL,F-49033 ANGERS 01,FRANCE
关键词
column liquid chromatography; cisplatin stability; cisplatin metabolites; platinum phosphato-derivatives;
D O I
10.1007/BF02466510
中图分类号
Q5 [生物化学];
学科分类号
071010 ; 081704 ;
摘要
Although cis-dichlorodiammineplatinum(II) (cisplatin or CDDP) is widely used for the treatment of several kinds of tumour, its stability and metabolism in biological fluids have not been completely elucidated. Conditions in which mobile phases of formic or phosphoric acids interact with platinum derivatives during chromatographic separation performed by high performance liquid chromatography on-line with inductively coupled plasma-mass spectrometry (ICPMS) are investigated. During chromatographic separation of CDDP the formic acid mobile phase does not interact with CDDP itself nor with its hydrolysis products. In contrast, the phosphoric acid mobile phase interacts, not with the CDDP itself but with its hydrolysis products which are present only in an aged aqueous solution, to generate two platinum phosphato-derivatives. This study suggests that the phosphoric acid has greater affinity for the CDDP hydrated complexes than formic acid and the latter is more appropriate for the study of cisplatin behavior in aqueous and biological media.
引用
收藏
页码:19 / 24
页数:6
相关论文
共 23 条
[1]   EVALUATION OF INDUCTIVELY COUPLED MASS-SPECTROMETRY FOR THE DETERMINATION OF PLATINUM IN PLASMA [J].
ALLAIN, P ;
BERRE, S ;
MAURAS, Y ;
LEBOUIL, A .
BIOLOGICAL MASS SPECTROMETRY, 1992, 21 (03) :141-143
[2]   The integrity of cisplatin in aqueous and plasma ultrafiltrate media studied by Pt-195 and N-15 nuclear magnetic resonance [J].
Briere, KM ;
Goel, R ;
Shirazi, FH ;
Stewart, DJ ;
Smith, ICP .
CANCER CHEMOTHERAPY AND PHARMACOLOGY, 1996, 37 (06) :518-524
[3]  
CALVERT H, 1993, CANCER SURV, V17, P189
[4]   STABILITY OF CISPLATIN, IPROPLATIN, CARBOPLATIN, AND TETRAPLATIN IN COMMONLY USED INTRAVENOUS SOLUTIONS [J].
CHEUNG, YW ;
CRADOCK, JC ;
VISHNUVAJJALA, BR ;
FLORA, KP .
AMERICAN JOURNAL OF HOSPITAL PHARMACY, 1987, 44 (01) :124-130
[5]   REACTION OF PLATINUM(II) ANTITUMOR AGENTS WITH SULFHYDRAL COMPOUNDS AND THE IMPLICATIONS FOR NEPHROTOXICITY [J].
CORDEN, BJ .
INORGANICA CHIMICA ACTA-BIOINORGANIC CHEMISTRY, 1987, 137 (1-2) :125-130
[6]   CISPLATIN METABOLITES - A METHOD FOR THEIR SEPARATION AND FOR MEASUREMENT OF THEIR RENAL CLEARANCE INVIVO [J].
DALEYYATES, PT ;
MCBRIEN, DCH .
BIOCHEMICAL PHARMACOLOGY, 1983, 32 (01) :181-184
[7]  
DALEYYATES PT, 1984, BIOCH PHARM, V33
[8]   ANALYSIS OF PLATINUM SPECIES ORIGINATING FROM CIS-DIAMMINEDICHLOROPLATINUM(II) (CISPLATIN) IN HUMAN AND RAT PLASMA BY HIGH-PERFORMANCE LIQUID-CHROMATOGRAPHY WITH ONLINE INDUCTIVELY COUPLED PLASMA ATOMIC EMISSION SPECTROMETRIC DETECTION [J].
DEWAAL, WAJ ;
MAESSEN, FJMJ ;
KRAAK, JC .
JOURNAL OF CHROMATOGRAPHY, 1987, 407 :253-272
[9]  
GAMELIN E, 1995, CHEMOTHER PHARM, V35, P97
[10]   STABILITY OF CISPLATIN IN AQUEOUS-SOLUTION [J].
GREENE, RF ;
CHATTERJI, DC ;
HIRANAKA, PK ;
GALLELLI, JF .
AMERICAN JOURNAL OF HOSPITAL PHARMACY, 1979, 36 (01) :38-43